Marker Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for MRKR, updated each market day.
MRKR AI Sentiment
AI predicts Marker Therapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Marker Therapeutics, Inc. Common Stock
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Sector
Exchange
Market Cap
$24,342,765
Cap Tier
Employees
5
Headquarters
HOUSTON, TX
Listed Since
Jan. 7, 1998
MRKR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MRKR Volatility
Marker Therapeutics, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
